PMID- 15772519
OWN - NLM
STAT- MEDLINE
DCOM- 20050715
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 45
IP  - 4
DP  - 2005 Apr
TI  - Effect of monthly atorvastatin and fenofibrate treatment on monocyte 
      chemoattractant protein-1 release in patients with primary mixed dyslipidemia.
PG  - 314-20
AB  - The aim of this study was to compare the effect of 30-day treatment with 
      atorvastatin and fenofibrate on monocyte release and plasma levels of monocyte 
      chemoattractant protein-1 (MCP-1). We studied 52 atherosclerotic patients with 
      primary mixed dyslipidemia and 16 age-, sex-, and weight-matched control subjects 
      with asymptomatic atherosclerosis. Dyslipidemic patients enrolled into the study 
      were randomly divided into three groups, simultaneously treated with atorvastatin 
      (20 mg/d, n = 18), fenofibrate (267 mg/d, n = 16), or placebo (n = 18). Plasma 
      lipid-profile and content of MCP-1, and monocyte release of this chemokine were 
      measured at baseline and after 30 days of therapy. Compared with the control 
      subjects, dyslipidemic patients exhibited the increased plasma levels and 
      monocyte MCP-1 release. Atorvastatin and fenofibrate not only improved lipid 
      profile but also decreased monocyte secretion of this chemokine. Moreover, 
      hypolipemic agents slightly reduced its plasma levels. MCP-1-lowering effect of 
      atorvastatin and fenofibrate did not correlate with the lipid-lowering potential 
      of these agents. Our results suggest that atorvastatin and fenofibrate produce 
      their antiinflammatory effect partially via inhibiting monocyte release of MCP-1. 
      The treatment-induced reduction in its secretion may contribute to the clinical 
      effectiveness of statins and fibrates in the therapy for atherosclerosis and 
      other chronic fibroproliferative diseases.
FAU - Okopien, Boguslaw
AU  - Okopien B
AD  - Department of Clinical Pharmacology, Medical University of Silesia, Katowice, 
      Poland.
FAU - Krysiak, Robert
AU  - Krysiak R
FAU - Haberka, Maciej
AU  - Haberka M
FAU - Herman, Zbigniew S
AU  - Herman ZS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Chemokine CCL2)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Atorvastatin
MH  - Chemokine CCL2/*metabolism
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Fenofibrate/*administration & dosage
MH  - Heptanoic Acids/*administration & dosage
MH  - Humans
MH  - Hyperlipidemias/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pyrroles/*administration & dosage
MH  - Statistics, Nonparametric
EDAT- 2005/03/18 09:00
MHDA- 2005/07/16 09:00
CRDT- 2005/03/18 09:00
PHST- 2005/03/18 09:00 [pubmed]
PHST- 2005/07/16 09:00 [medline]
PHST- 2005/03/18 09:00 [entrez]
AID - 00005344-200504000-00007 [pii]
AID - 10.1097/01.fjc.0000156821.50457.32 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2005 Apr;45(4):314-20. doi: 
      10.1097/01.fjc.0000156821.50457.32.